Pirarubicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pirarubicin
Accession Number
DB11616
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Adriamycin, tetrahydropyranyl
  • Theprubicin
  • THP-Adm
  • THP-Doxorubicin
Product Ingredients
IngredientUNIICASInChI Key
Pirarubicin hydrochlorideE7V83174BE95343-20-7ZPHYPKKFSHAVOE-YZIXBPQXSA-N
Categories
UNII
D58G680W0G
CAS number
72496-41-4
Weight
Average: 627.643
Monoisotopic: 627.231575635
Chemical Formula
C32H37NO12
InChI Key
KMSKQZKKOZQFFG-YXRRJAAWSA-N
InChI
InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21+,22-,31+,32-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yloxy]oxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
[H][[email protected]]1(N)C[[email protected]]([H])(O[[email protected]@]2([H])C[[email protected]@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[[email protected]@]([H])(C)[[email protected]@]1([H])O[[email protected]]1([H])CCCCO1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pirarubicin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pirarubicin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumPirarubicin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidPirarubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Pirarubicin.Approved, Investigational
AmpicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumPirarubicin may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylatePirarubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pirarubicin.Investigational
BendazacBendazac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Pirarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pirarubicin.Approved, Investigational
BevoniumBevonium may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
Botulinum Toxin Type APirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BPirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pirarubicin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirarubicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Pirarubicin.Approved
CarbenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Pirarubicin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinPirarubicin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Pirarubicin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
CisatracuriumPirarubicin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylatePirarubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Pirarubicin.Approved
Clodronic AcidPirarubicin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pirarubicin.Approved
CloxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethatePirarubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pirarubicin.Approved
CurcuminCurcumin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pirarubicin.Approved, Investigational
CyclosporinePirarubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Pirarubicin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
DecamethoniumPirarubicin may increase the respiratory depressant activities of Decamethonium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pirarubicin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pirarubicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pirarubicin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Pirarubicin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pirarubicin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirarubicin.Approved, Investigational
Domoic AcidPirarubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chloridePirarubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pirarubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
Etidronic acidPirarubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
FingolimodPirarubicin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FloctafenineFloctafenine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Pirarubicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Pirarubicin.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Pirarubicin.Investigational
GallaminePirarubicin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodidePirarubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pirarubicin.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Pirarubicin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pirarubicin.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pirarubicin.Approved, Withdrawn
HigenamineHigenamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
IbandronatePirarubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Pirarubicin.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pirarubicin.Investigational
IsoxicamIsoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pirarubicin.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Leflunomide.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Pirarubicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
MecamylaminePirarubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Pirarubicin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pirarubicin.Experimental
MetocurinePirarubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodidePirarubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumPirarubicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Pirarubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Natalizumab.Approved, Investigational
NeosaxitoxinPirarubicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Pirarubicin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Pirarubicin.Approved
OxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirarubicin.Approved, Vet Approved
PamidronatePirarubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumPirarubicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Pirarubicin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Pirarubicin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pirarubicin.Experimental
PhenoxymethylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirarubicin.Approved, Investigational
PipecuroniumPirarubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Pirarubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Pirarubicin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pirarubicin.Experimental
PTC299PTC299 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PyrantelPirarubicin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pirarubicin.Approved
RapacuroniumPirarubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Experimental, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pirarubicin.Investigational
RisedronatePirarubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumPirarubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Pirarubicin.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Pirarubicin.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Pirarubicin.Approved
SalicylamideSalicylamide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Pirarubicin.Approved
SalsalateSalsalate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirarubicin.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pirarubicin.Investigational
SRT501SRT501 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
SuccinylcholinePirarubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Pirarubicin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pirarubicin.Approved, Investigational
TalampicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Pirarubicin can be decreased when it is combined with Tazobactam.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Pirarubicin.Investigational
Technetium Tc-99m etidronatePirarubicin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronatePirarubicin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Pirarubicin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Pirarubicin.Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Pirarubicin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidPirarubicin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
TofacitinibPirarubicin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Pirarubicin.Approved
TranilastTranilast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pirarubicin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
TubocurarinePirarubicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Pirarubicin.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Pirarubicin.Approved
VecuroniumPirarubicin may increase the respiratory depressant activities of Vecuronium.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Pirarubicin.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidPirarubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01885
PubChem Compound
11296583
PubChem Substance
347828009
ChemSpider
9471567
ChEBI
94770
ChEMBL
CHEMBL2354444
Wikipedia
Pirarubicin
ATC Codes
L01DB08 — Pirarubicin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingPreventionBladder Recurrence / Nephroureterectomy / Upper Tract Urothelial Carcinoma1
2RecruitingPreventionBladder Recurrence / Upper Tract Urothelial Carcinoma1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentIntravesical Instillation1
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2, 3RecruitingTreatmentOverall Survival / Progression-free Survival / Toxicity1
3CompletedTreatmentNeoplasms, Breast1
3RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentCancer, Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.301 mg/mLALOGPS
logP2.06ALOGPS
logP2.05ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.99ChemAxon
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area204.3 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity157.38 m3·mol-1ChemAxon
Polarizability64.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Anthracyclines
Sub Class
Not Available
Direct Parent
Anthracyclines
Alternative Parents
Tetracenequinones / Aminoglycosides / Anthraquinones / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / Alkyl aryl ethers / Oxanes / Monosaccharides
show 11 more
Substituents
Anthracycline / Anthracyclinone-skeleton / Aminoglycoside core / Tetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Glycosyl compound / O-glycosyl compound / Tetralin
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on August 25, 2016 16:58 / Updated on December 01, 2017 17:29